GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Pluri Inc.
Pluri is an Israeli biotech company developing cell therapies. Its stock price is a venture bet on its 3D cell culture technology. The stock price reflects high volatility and reliance on news about clinical trials and partnerships.
Share prices of companies in the market segment - Pharma metabolism
Pluri Inc. is an Israeli biotech company that uses its 3D cell culture platform for applications in medicine and other industries. We've categorized it as a Pharma: Metabolism company. The chart below shows how the market values companies at the forefront of cell technology.
Broad Market Index - GURU.Markets
Pluri is an Israeli biotech company that uses its 3D cell culture platform for applications in medicine and other industries. As a component of the GURU.Markets index, it operates at the forefront of cell technology. The chart below is for the US market. See how this company's stock compares to the US market.
Change in the price of a company, segment, and market as a whole per day
PLUR - Daily change in the company's share price Pluri Inc.
Pluri Inc.'s daily price change reflects the high volatility inherent in cell therapy companies. This metric measures the stock's sensitivity to news about clinical trials of its products and technology platform.
Daily change in the price of a set of shares in a market segment - Pharma metabolism
Pluri Inc. is a biotech company. This chart highlights the sector's high volatility. Comparing it to PLUR, with its 3D cell culture platform, helps to assess it as a high-risk tech stock.
Daily change in the price of a broad market stock, index - GURU.Markets
Pluri is an Israeli biotech company that has developed 3D cell growth technology for the creation of various therapeutic products. The company's shares are a bet on the future of regenerative medicine. Their high volatility reflects the risks and prospects of breakthrough technologies.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Pluri Inc.
For Pluri Inc., formerly Pluristem Therapeutics, the year-over-year performance is a story of its transformation into a diversified biotech company. Its market capitalization over the past 12 months reflects its new strategy, which includes cell therapy, the production of cultured coffee, and other innovative areas.
Annual dynamics of market capitalization of the market segment - Pharma metabolism
Pluri Inc. is a biotech company with a unique 3D cell culture platform with applications ranging from drug development to the food industry. This chart shows how the market views its innovative yet capital-intensive technology and its path to commercialization across various sectors.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Pluri is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of its cell therapy platform trials. The company's chart exists in a world of its own, where data releases are the key events.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Pluri Inc.
Pluri is a biotech company with a 3D cell culture platform. Its monthly performance reflects progress across its various programs, from medicine to agritech. News of partnerships or technological breakthroughs in any of these areas can be a catalyst.
Monthly dynamics of market capitalization of the market segment - Pharma metabolism
Pluri Inc. (formerly Pluristem) develops placenta-based cell therapy for a variety of diseases. This sector of regenerative medicine promises to revolutionize treatment. The chart below reflects the changing hopes and fears of investors regarding cell technologies and their long and expensive journey from the lab to the patient.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Pluri is an Israeli biotech company using cell-based technologies for a variety of applications. Its stock price is driven by clinical trial successes and partnerships. It's a company driven by science and innovation, not by general market trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Pluri Inc.
Pluri is an Israeli biotech company focused on cell therapy using 3D technology. Its weekly stock price is volatile, driven by news about clinical trials, partnerships, and the progress of its unique manufacturing platform, which attracts investor attention.
Weekly dynamics of market capitalization of the market segment - Pharma metabolism
Pluri is an Israeli biotech company focused on cell therapy using 3D technology. Its weekly stock price is volatile, driven by news about clinical trials, partnerships, and the progress of its unique manufacturing platform, which attracts investor attention.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Pluri, a biotech company, lives in a world of its own. Its performance is driven by news of scientific breakthroughs. A chart comparing the stock to the S&P 500 clearly demonstrates how the stock can rise or fall on company-specific events, completely ignoring the broader market.
Market capitalization of the company, segment and market as a whole
PLUR - Market capitalization of the company Pluri Inc.
Pluri's market capitalization tells the story of an Israeli biotech company developing cell therapy based on placenta cells. Its chart reflects its long history of research and development. Its dynamics visualize how investors assess the potential of its 3D platform for creating cell-based products for various diseases.
PLUR - Share of the company's market capitalization Pluri Inc. within the market segment - Pharma metabolism
Pluri Inc. is a biotech company that has developed a 3D cell culture platform with potential applications in regenerative medicine and the food industry. Its market capitalization reflects the potential of its versatile technology. The chart below shows how investors value its various segments.
Market capitalization of the market segment - Pharma metabolism
Pluri (formerly Pluristem) develops placenta-derived cell therapies for the treatment of various diseases. The chart below shows the overall market capitalization of the pharmaceutical sector. It illustrates the potential of cell therapy as a new pillar of medicine, alongside small molecules and biologics.
Market capitalization of all companies included in a broad market index - GURU.Markets
Shown here is 3D printing of cells. Pluri is developing technology for the mass production of cells that could be used to create cell therapies or even cultured meat. Its line on the graph represents a bet that this platform will become the foundation for a new industrial revolution in biotechnology.
Book value capitalization of the company, segment and market as a whole
PLUR - Book value capitalization of the company Pluri Inc.
Pluri's foundation is its 3D cell culture platform, which can be used in medicine, food, and agriculture. This represents unique biotech capital. This chart shows how the Israeli company, formerly known as Pluristem, is transforming its capital base to realize the broad potential of its technology.
PLUR - Share of the company's book capitalization Pluri Inc. within the market segment - Pharma metabolism
Pluri is a biotechnology company that uses a unique 3D platform to grow cells for various therapeutic applications. Its assets include its bioreactors and manufacturing facilities. The chart shows the company's share of this cutting-edge cell therapy infrastructure.
Market segment balance sheet capitalization - Pharma metabolism
Cell technologies, as the BCap_Ges chart for biotech shows, are a capital-intensive niche. Pluri Inc., developing 3D cell culture technology, must invest in complex bioreactors and production facilities. Its science requires a robust industrial base.
Book value of all companies included in the broad market index - GURU.Markets
Pluri's assets include unique 3D bioreactors and production facilities for industrial-scale cell cultivation. The book value reflects the physical capital invested in creating "cell farms," which could become the basis for regenerative medicine and even cultured meat production.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Pluri Inc.
Pluri is a biotech company working with placenta cells to create therapeutic products. Its value lies in its unique 3D cell culture technology. Its book value is low. Its market capitalization is a bet on its scientific platform. The MvsBCap chart will reflect progress in clinical trials across various areas.
Market to book capitalization ratio in a market segment - Pharma metabolism
Pluri Inc. (formerly Pluristem) is a biotech company developing cell therapies. Its value lies in its unique 3D cell culture platform. The chart shows how the market views its technology and its potential for medical applications.
Market to book capitalization ratio for the market as a whole
Pluri Inc. (formerly Pluristem) has developed a platform for 3D cell growth that can be used to create cell therapies and even cultured meat. Its market valuation reflects the enormous potential of this versatile technology. The chart shows the premium investors pay for such breakthrough platform biotechnologies.
Debts of the company, segment and market as a whole
PLUR - Company debts Pluri Inc.
Pluri, a biotech company developing a cell production platform, uses capital to fund its research in various fields, from medicine to food. Developing such a versatile technology requires enormous investment. This chart shows how the company funds its ambitious projects at the forefront of cell technology.
Market segment debts - Pharma metabolism
Pluri Inc. is a biotech company that has developed a 3D cell therapy platform. Scaling up cell production for therapeutic purposes is a complex and expensive task. This chart shows how Pluri is funding its innovative manufacturing technology and advancing its cell products through clinical trials.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Pluri Inc.
Pluri Inc. is involved in cell therapy, and this chart reflects its financial dependence on external capital to conduct long-term research. High debt for a biotech company is a bet on a scientific breakthrough. Failure in clinical trials could make servicing this debt impossible and threaten the company's survival.
Market segment debt to market segment book capitalization - Pharma metabolism
Pluri Inc. is a biotechnology company developing cell-based products for various therapeutic applications. This chart shows the company's debt burden in the regenerative medicine sector. It helps understand how the company finances its extensive and capital-intensive research platform compared to other players in this cutting-edge field.
Debt to book value of all companies in the market
Pluri Inc. is a biotech company that has developed a 3D cell therapy platform for various fields, including regenerative medicine. The overall debt level, shown in the chart, determines the investment climate. For an innovative company seeking financing, access to capital is key to development and commercialization.
P/E of the company, segment and market as a whole
P/E - Pluri Inc.
A chart of Pluri Inc., a cell therapy company, shows how investors value its 3D cell growth platform. The high values reflect hopes that this technology will find applications in regenerative medicine, food production, and other industries.
P/E of the market segment - Pharma metabolism
This chart shows the average P/E for the biotech sector, where Pluri develops cell technologies. The industry's high valuation reflects a belief in regenerative medicine. This metric provides context for assessing how revolutionary the market considers Pluri's 3D cell culture platform.
P/E of the market as a whole
Pluri is a biotech company using its 3D cell culture platform for a variety of therapeutic and commercial applications, from medicine to food production. This chart charts the biotech market sentiment. It helps understand how the market views the potential of this versatile cell platform and whether it believes in Pluri's ability to commercialize its developments in such diverse fields.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Pluri Inc.
Pluri Inc. is a biotech company that has developed a 3D cell growth platform that can be used to create cell therapies. The company's valuation is based on the potential of its technology. This chart demonstrates analysts' belief that Pluri's platform can be used to create effective drugs and other products.
%20P%2FE%20Pluri%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Pluri-Inc.&v=1772596819742 "Chart of the company's future (projected) P/E Pluri Inc.")
Future (projected) P/E of the market segment - Pharma metabolism
Pluri Inc. has developed 3D cell culture technology that enables the mass production of cells for use in medicine, food, and agriculture. This graph shows its future profitability expectations, allowing one to assess how highly the market values its platform as a foundation for future innovation.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-metabolism&v=1772596819832 "Future (projected) P/E graph of the market segment - Pharma metabolism")
Future (projected) P/E of the market as a whole
Pluri Inc. is a biotech company using a unique 3D platform to create cell-based products. This is fundamental science with broad potential applications. This chart, reflecting investor risk appetite, is critical. During periods of optimism, the market is more willing to fund platform biotech companies like Pluri.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772596819846 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Pluri Inc.
Pluri Inc. uses its 3D platform to grow cells that can be used in cell therapy and the production of cultured meat. The company's profitability is a long-term goal, dependent on the commercialization of its technology. This chart shows how much the company is investing in creating a platform that could revolutionize medicine and the food industry.
Profit of companies in the market segment - Pharma metabolism
Pluri (formerly Pluristem) is a biotech company developing placental cell-based therapies for the treatment of various diseases. Its technology enables the creation of "off-the-shelf" drugs. This graph reflects the high potential in the regenerative medicine sector, where cell technologies promise to treat diseases previously considered incurable.
Overall market profit
Pluri Inc. is developing a 3D cell culture platform for applications in medicine and other industries. This is a cutting-edge technology that requires significant investment. The overall economic climate, reflected in this chart, influences the availability of venture capital and the willingness of partners to invest in revolutionary manufacturing processes.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Pluri Inc.
Pluri is a biotech company that has developed a unique 3D cell culture platform that could be used to create cell therapies and even cultured meat. This chart reflects analysts' expectations regarding the commercialization of this promising platform across various industries.
%20profit%20of%20the%20company%20Pluri%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Pluri-Inc.&v=1772596820092 "Graph of future (projected) profit of the company Pluri Inc.")
Future (predicted) profit of companies in the market segment - Pharma metabolism
Pluri Inc. is a biotech company that has developed a 3D cell culture platform that could be used to create cell therapies and even produce cultured meat. This chart shows profitability forecasts for the biotech sector. It reflects interest in breakthrough platforms that could find application in medicine and the food industry.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-metabolism&v=1772596820117 "Graph of future (predicted) profits of companies in a market segment - Pharma metabolism")
Future (predicted) profit of the market as a whole
Pluri Inc. is a biotech company developing cell-based products for various therapeutic applications. Its development is funded by investors and depends on confidence in its platform. This graph, reflecting overall market sentiment, impacts the availability of capital for companies operating at the cutting edge of science but with a long-term payback horizon.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772596820156 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Pluri Inc.
Pluri Inc. uses 3D cell growth technology for a variety of applications, from medicine to food. This chart shows the market valuation of its breakthrough platform. The high valuation relative to revenue reflects its belief in its potential to transform numerous industries.
P/S market segment - Pharma metabolism
Pluri Inc. is a biotech company that has developed a 3D cell culture platform for the creation of cell therapies and other products. This chart reflects the average revenue estimate in the biotech sector. It allows one to estimate the premium investors are willing to pay for Pluri's innovative manufacturing platform and its potential applications in medicine and other industries.
P/S of the market as a whole
Pluri Inc., formerly Pluristem, uses a unique 3D platform to grow cells that can be used to create a variety of therapeutic products, from medicine to food. Their technology is a universal "cell factory." This chart provides a general revenue metric against which to evaluate the broad potential of Pluri's technology platform.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Pluri Inc.
Pluri Inc. uses its 3D cell culture technology to develop products in regenerative medicine, agriculture, and food. This chart reflects investor expectations for this multidisciplinary platform. The valuation is based on potential future revenue from partnerships and the commercialization of its cell products.
%20P%2FS%20Pluri%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Pluri-Inc.&v=1772596820278 "The graph of the company's future (projected) P/S Pluri Inc.")
Future (projected) P/S of the market segment - Pharma metabolism
Pluri Inc. is a biotech company that has developed a 3D cell expansion platform that enables the mass production of cells for therapeutic and commercial applications, such as cultured meat. This chart shows how the market values its innovative production technology compared to the biotech sector.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-metabolism&v=1772596820306 "Future (projected) P/S market segment graph - Pharma metabolism")
Future (projected) P/S of the market as a whole
Pluri Inc. is a biotech company that has developed a 3D cell culture platform that can be used to create a variety of cell therapies. This chart, reflecting investor willingness to fund advanced biotech manufacturing technologies, is important for Pluri. Market optimism facilitates capital raising and partnerships with pharmaceutical companies.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772596820416 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Pluri Inc.
Pluri Inc. is a biotech company that has developed a platform for 3D cell growth that can be used in regenerative medicine and cultured meat production. This chart reflects revenue from partnerships and cell product sales. It demonstrates the commercialization of this cutting-edge cell manufacturing technology.
Sales of companies in the market segment - Pharma metabolism
Pluri Inc. is a biotechnology company that uses its unique 3D platform to grow cells and develop products for regenerative medicine, agritech, and the food industry. The company's business is divided into these three innovative segments. This chart shows revenue from one of them, reflecting the commercialization of cell technologies.
Overall market sales
Pluri Inc. is a biotechnology company that has developed a platform for 3D cell cultivation at scale. This technology can be used to develop cell therapies and in areas such as cultured meat production. The company operates at the intersection of medicine and sustainable technologies, creating the potential for several breakthrough markets.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Pluri Inc.
Pluri (formerly Pluristem) is a biotechnology company developing placental cell-based therapies for the treatment of various diseases. It also has interests in agritech and cultured meat production. Its future sales forecast reflects expectations for the commercialization of its diverse and innovative cell technologies.
%20sales%20of%20the%20company%20Pluri%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Pluri-Inc.&v=1772596820698 "Schedule of future (projected) sales of the company Pluri Inc.")
Future (projected) sales of companies in the market segment - Pharma metabolism
Pluri Inc. is a biotech company that has developed 3D cell culture technology with potential applications in regenerative medicine and the food industry. This chart shows expectations for the entire cell technology sector and helps assess the progress analysts are predicting in cell product development.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-metabolism&v=1772596820736 "Schedule of future (projected) sales of companies in the market segment - Pharma metabolism")
Future (projected) sales of the market as a whole
Pluri Inc. develops cell therapy technologies. Like most development-stage biotech companies, it relies on external funding for research. This graph of overall sales forecasts reflects overall market sentiment, which impacts the availability of capital for innovative projects.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772596820962 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Pluri Inc.
Pluri Inc. is a biotech company that has developed a 3D cell culture platform that can be used to create cell therapies and even cultured meat. This chart depicts its financial trajectory, where investments in scaling its unique production technology are key to future profitability across various industries.
Market segment marginality - Pharma metabolism
Pluri Inc. is a biotech company using its 3D cell growth platform for industrial scale cell therapy. The effectiveness of their technology could solve the industry's biggest challenge—production costs. The graph shows their operating costs as they work toward a revolution in regenerative medicine.
Market marginality as a whole
Pluri Inc. is a biotech company that has developed a 3D cell culture platform that could be used to create cell therapies and even cultured meat. This chart shows the profitability of existing businesses, while PLUR's value is determined by the potential of its versatile platform to transform several major industries.
Employees in the company, segment and market as a whole
Number of employees in the company Pluri Inc.
Pluri develops cell therapies using its unique 3D cell culture technology. This graph shows its team of scientists and manufacturing specialists. The size of this team reflects the investment in scaling their proprietary platform for industrial-scale cell product production.
Share of the company's employees Pluri Inc. within the market segment - Pharma metabolism
Pluri Inc. (formerly Pluristem) is developing cell therapy based on placenta cells. Its unique 3D cell culture technology requires a team of biologists and engineers. This chart illustrates its extensive workforce in the cutting-edge field of regenerative medicine, which holds promise for treating a wide range of diseases.
Number of employees in the market segment - Pharma metabolism
Pluri Inc. has developed 3D cell culture technology to create cell therapy products and even cultured meat. This chart reflects employment in the metabolic research and biotechnology sector. The growing number of cell biologists points to a revolution in regenerative medicine and the search for sustainable protein sources, where Pluri's technology could find application.
Number of employees in the market as a whole
Pluri Inc. is a biotech company using 3D cell expansion to create cell-based products. Its growth depends on research success and partnerships. This chart shows the overall economics, but for Pluri, proving the effectiveness of its platform is more important to attract investment and expand.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Pluri Inc. (PLUR)
Pluri Inc. (formerly Pluristem) is a biotech company developing cell therapies. The high market capitalization per employee in this chart is a classic example of biotech. The market is evaluating the potential of their 3D cell growth technology to create new treatments, which is intellectual capital, not physical capital.
%20of%20the%20company%20Pluri%20Inc.%20(PLUR)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Pluri-Inc.-PLUR&v=1772596821527 "Chart of market capitalization per employee (in thousands of dollars) of the company Pluri Inc. (PLUR)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma metabolism
Pluri Inc. is a biotechnology company using 3D cell expansion to create cell-based products for various industries, including medicine and food. This metric reflects how the market perceives their unique production platform and its potential. It is a measure of the technology's value relative to the team developing it.
%20by%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-metabolism&v=1772596821600 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma metabolism")
Market capitalization per employee (in thousands of dollars) for the overall market
Pluri Inc. is a biotech company that has developed a 3D cell culture platform that can be used to create cell therapies and even cultured meat. The chart demonstrates the high market acceptance of this innovative production platform with broad potential applications.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772596821669 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Pluri Inc. (PLUR)
Pluri Inc. is a biotech company using a unique 3D cell culture platform. They can produce cells (such as stem cells) on a large scale for therapeutic purposes and even for "cultured meat." This graph shows how close the company is to commercializing their platform. It measures how far their team of scientists and technicians is turning this technology into profitable products.
%20Chart%20Pluri%20Inc.%20(PLUR)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Pluri-Inc.-PLUR&v=1772596821805 "Company Profit Per Employee (in thousands of dollars) Chart Pluri Inc. (PLUR)")
Profit per employee (in thousands of dollars) in the market segment - Pharma metabolism
Pluri Inc. is a biotech company that has developed a 3D cell manufacturing platform that can be used to create drugs and even cultured meat. Their success depends on scaling this technology. This chart shows how productive their team is in commercializing their unique platform compared to other biotech companies.
%20in%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-metabolism&v=1772596821869 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma metabolism")
Profit per employee (in thousands of dollars) for the market as a whole
Pluri (PLUR) is a biotech company using 3D cell growth technology (cell therapy). It's an R&D platform. Negative profit per employee is the norm. The chart shows the "cost" of the team of scientists working on this complex technology platform, which doesn't yet generate revenue.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772596821922 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Pluri Inc. (PLUR)
Pluri is a biotech company that has developed a 3D platform for cell production. This graph shows the potential of its technology. Growth in revenue per employee will depend on partnerships in areas such as cell therapy or even cultured meat production.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Pluri-Inc.-PLUR&v=1772596821957 "Sales chart per company employee Pluri Inc. (PLUR)")
Sales per employee in the market segment - Pharma metabolism
Pluri Inc. (formerly Pluristem) is a biotech company using 3D technology to grow cells (from placenta) to develop cell therapies. This chart compares revenue per employee (R&D) to the industry average. It reflects how productive their unique 3D cell production platform is at the research stage.
Sales per employee for the market as a whole
Pluri Inc. (PLUR) is a biotech company using a unique 3D platform to grow cells, which are then used to create therapies (for example, for muscle repair) or even "cultured meat." This is an R&D platform. This chart will show $0 or partnership revenue, as their technology is still in the development stage.
Short shares by company, segment and market as a whole
Shares shorted by company Pluri Inc. (PLUR)
Pluri (PLUR) is an Israeli biotech company using 3D technology to grow cells (including stem cells) for therapeutic purposes. This is fundamental science, far from commercialization. This chart shows the number of investors who consider this technology too speculative and are betting that it will not prove effective.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Pluri-Inc.-PLUR&v=1772596822091 "Short Shares Chart for the Company Pluri Inc. (PLUR)")
Shares shorted by market segment - Pharma metabolism
Pluri is a biotech company using its 3D platform to create cell-based products aimed at medicine and even "cultured meat." It's a cutting-edge but highly speculative sector. This chart shows a collective short squeeze on the cell therapy industry, reflecting investor doubts that this technology will soon become profitable.
Shares shorted by the overall market
Pluri Inc. is involved in cutting-edge cell technologies and 3D bioprinting. This is pure science. This chart reflects total market pessimism. For biotech companies in the R&D stage, this is mortally dangerous. Market fears are drying up available capital, which companies vitally need to conduct expensive clinical trials.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Pluri Inc. (PLUR)
Pluri Inc. is a biotech company developing placenta-derived cell therapy for inflammatory and immune diseases. Like many biotechs, the company's shares are driven by trial news. This oscillator measures the market's "temperature," showing when the stock is "overheated" (above 70) in anticipation of a breakout or "oversold" (below 30) due to a lack of news.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Pluri-Inc.-PLUR&v=1772596822257 "RSI 14 indicator chart for the company's stock Pluri Inc. (PLUR)")
RSI 14 Market Segment - Pharma metabolism
Pluri Inc. is a biotech company that uses its 3D platform for scalable cell production. These technologies are applied in both regenerative medicine (cell therapy) and agritech (for example, coffee cultivation). This chart shows the overall "temperature" in the volatile cell therapy and biotech sectors. It helps separate PLUR's performance from the general "hype" that has gripped the entire industry.
RSI 14 for the overall market
Pluri (PLUR), a biotech company, is critically dependent on this chart. Its survival depends on funding R&D. During periods of market euphoria, investors are willing to invest generously in risky but breakthrough research. During periods of panic, risk appetite vanishes, and companies burning through cash risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast PLUR (Pluri Inc.)
Pluri Inc. is a biotech company using 3D cell growth technology (cell therapy) to treat various diseases. This chart shows the average target price. Analysts' forecasts are based on an assessment of its manufacturing platform and progress in clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-PLUR-Pluri-Inc.&v=1772596822383 "A chart showing analyst consensus forecasts for the expected stock price. PLUR (Pluri Inc.)")
The difference between the consensus estimate and the actual stock price PLUR (Pluri Inc.)
Pluri is an Israeli biotech company with a unique 3D platform for "growing" placenta cells. Their goal is to use these cells for regenerative medicine. This chart shows the difference between the market valuation and the consensus forecast. It reveals whether experts believe in this complex but promising cell technology.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-PLUR-Pluri-Inc.&v=1772596822430 "A chart showing the difference between the consensus forecast and the actual stock price. PLUR (Pluri Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma metabolism
Pluri is an Israeli biotech company that uses its 3D platform to "grow" placental cells. It is exploring applications in medicine and even in "cellular" meat. This chart shows general expectations for the metabolism sector, reflecting whether experts believe in the commercial success of cellular technologies.
Analysts' consensus forecast for the overall market share price
Pluri is an Israeli biotech company that has developed a 3D cell-growing platform (cell therapy) for treating inflammation, muscle injuries, and even "growing" coffee. This chart shows the overall risk appetite. For Pluri, a company with an innovative but risky platform, overall market optimism (risk appetite) is critical for R&D funding.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Pluri Inc.
Pluri (formerly Pluristem) is an Israeli pioneer in cell therapy. Their signature feature is a 3D bioreactor that grows stem cells (from placenta) on an industrial scale to treat inflammation and regenerative processes. This graph is a clear indicator of faith in their R&D. It reflects their (very long) path to commercialization and their recent pivot to cellular meat.
AKIMA Market Segment Index - Pharma metabolism
Pluri Inc. (PLUR) is an Israeli biotech company that uses its 3D platform to grow cells (from placenta) on an industrial scale. They are targeting the treatment of inflammatory and hematological diseases. The chart shows the average index for the segment, helping investors assess how this cell factory platform compares to the sector average.
The AKIM Index for the overall market
Pluri is a biotech company using 3D cell culture technologies for medical applications (cell therapy) and food (cultured meat). This chart, which reflects the market average, is just a backdrop. It helps put this dual-use platform into perspective against broader economic trends.
